SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

Sun Pharma Advanced Research Company Limited

SPARC

INE232I01014

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:49 2024-04-19 am EDT			5-day change	1st Jan Change
332.6 ^INR	-5.00%		-18.54%	+15.95%

Apr. 15	Transcript : Sun Pharma Advanced Research Company Limited - Special Call
Apr. 10	Sun Pharma Advanced Research Company Limited Announces Results from the Planned Interim Analysis of the PROSEEK Study of Vodobatinib in Patients with Early Parkinson's Disease	CI

Rights Issue: 1 new share @ 67 INR for 7 existing shares

August 22, 2012

MarketScreener.com By The editorial team

Latest news about Sun Pharma Advanced Research Company Limited

Transcript : Sun Pharma Advanced Research Company Limited - Special Call	Apr. 15
Sun Pharma Advanced Research Company Limited Announces Results from the Planned Interim Analysis of the PROSEEK Study of Vodobatinib in Patients with Early Parkinson's Disease	Apr. 09	CI
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 05	CI
Transcript : Sun Pharma Advanced Research Company Limited - Special Call	Jan. 06
Transcript : Sun Pharma Advanced Research Company Limited - Special Call	Nov. 16
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 06	CI
Sun Pharma Advanced Research Company Limited Announces Retirement of Chitturi Trinadha Rao as Senior Vice President, Drug Discovery	Nov. 02	CI
Sun Pharma Advanced Research Company Ltd. Completes Enrolment in Proosek, A Global Phase 2 Study of Vodobatinib in Early Parkinson's Disease	23-10-29	CI
Sun Pharma Advanced Research Company Limited Announces Incorporation of Wholly Owned Subsidiary Company	23-09-26	CI
Sun Pharma Advanced Research Company Limited Appoints Kajal Damania as Company Secretary	23-09-22	CI
Sun Pharma Advanced Research Company Limited Announces the Resignation of Mr. Dinesh Lahoti as Company Secretary and Compliance Officer	23-09-11	CI
Sun Pharma Advanced Research Company Limited Announces Resignation of Dinesh Lahoti as Company Secretary and Compliance Officer, Effective September 11, 2023	23-08-07	CI
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-07	CI
Sun Pharma Advanced Research Company Limited Announces That FDA Issues Complete Response Letter for Pdp-716 Nda Due to Inspection Findings At Third-Party Api Manufacturing Facility	23-07-13	CI
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-22	CI
Indian shares open higher as SVB acquisition hopes aid sentiment	23-03-27	RE
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Sun Pharma Advanced's Partner Launches Neonatal Seizure Drug SEZABY in US	23-01-25	MT
Sun Pharma Advanced, Sun Pharma Get US FDA Nod for Neonatal Seizures Treatment Drug	22-11-17	MT
Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Limited Announces U.S. FDA Approval of SEZABY (Phenobarbital Sodium Powder for Injection) for the Treatment of Neonatal Seizures	22-11-17	CI
Sun Pharma Unit and SPARC Sign Licensing Deal for Neonatal Seizure Drug in US	22-11-09	MT
Sun Pharma and Sun Pharma Advanced Research Company Ltd Sign Licensing Agreement	22-11-09	CI
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-07	CI
Transcript : Sun Pharma Advanced Research Company Limited - Special Call	22-10-13
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-08	CI

Chart Sun Pharma Advanced Research Company Limited

Duration

Period

Chart Sun Pharma Advanced Research Company Limited

More charts

Sun Pharma Advanced Research Company Limited is an India-based clinical-stage bio-pharmaceutical company. The Company is in the business of research and development (R&D) of pharmaceutical products to unmet medical needs in the areas of oncology, neurodegeneration and immunology. The Company develops New Chemical Entities (NCE), New Biological Entities and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its Novel Drug Delivery Systems (NDDS) include Wrap Matrix Technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology is useful to develop controlled release tablets. It has developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. It has also developed Xelpros, a BAK free latanoprost eye drop developed using Lipexelle technology. Xelpros is commercialized by its partner in the United States. It has also developed PDP-716 eye drops for treatment of Glaucoma based on its TearAct technology.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED	+15.95%	1.36B
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B